laboratori corp america hldg
analyst day preview see proof
point global life strategi
labcorp analyst day tomorrow believ compani posit show
proof point global life scienc strategi deliv valu custom
sharehold believ labcorp approach align well two over-arch
theme healthcar push toward find way reduc cost system
engag patient better consum healthcar believ labcorp
beneficiari trend diagnost drug develop
leverag industry-lead scale advanc technolog tool provid valu
patient provid payor life scienc sponsor evolv healthcar
case stock rais pt long-term ep growth forecast
trend believ long-term structur trend healthcar favor low cost provid
diagnost ps patient consumer payor strategi price
transpar pama increasingli drive valu low cost provid labcorp
quest believ payor contract evolv toward valu away
rate see real strateg posit nation lab labcorp quest
exclus contract nation payer aetna respect open
in-network access lab drug develop focu drug price
econom valu therapeut drive share toward low cost servic provid
uniqu busi offer believ breadth scale capabl labcorp
offer drug develop provid competit advantag versu peer proof
point includ diagnost post revenu growth best sinc
drug develop post net book-to-bil best amongst peer
trend believ labcorp go demonstr compani invest
technolog tool data patient access allow better engag patient
consumer-friendli way proof point includ statist patient
opted-in clinic trial enrol patient seen labcorp walgreen
either new labcorp seen last year compani
execut million covanc cost synergi
lh quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay laboratori corp america hldg
laboratori corp america hldg lh
overweight labcorp remark track
record execut led lead organ
growth augment value-enhanc
acquisit covanc acquisit continu
theme expect expertis
organ posit labcorp premier
partner choic companion diagnost play
greater role clinic decis make
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceelr revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
barclay laboratori corp america hldg
labcorp analyst day tomorrow believ compani posit show
proof point global life scienc strategi deliv valu custom
sharehold believ labcorp approach align well two over-arch theme
healthcar push toward find way reduc cost system engag
patient better consum healthcar believ labcorp beneficiari
trend diagnost drug develop leverag industry-
lead scale advanc technolog tool provid valu patient provid payor
life scienc sponsor evolv healthcar industri
rais price rais long-term ep growth
forecast labcorp price repres ebitda forecast
billion also repres ep prior price target
repres ebitda forecast shown chart
convict compani strategi durabl free cash flow give us greater
convict long-term ep trajectori compani beyond forecast
ep growth roughli per year vs consensu roughli per year
trend believ labcorp aggreg share
provid diagnost drug develop
believ long-term structur trend healthcar favor low cost provid
labcorp benefit across diagnost drug develop diagnost
labcorp quest far away low cost provid test
consolid drive growth acceler ps patient consumer payor
strategi price transpar pama increasingli drive valu low cost
provid believ payor contract evolv toward valu away rate
drive share aggreg toward nation lab see real strateg
posit nation lab labcorp quest exclus contract nation payer
 aetna respect open in-network access lab
market like contract begin difficult us see lab
get penal way well drug develop focu drug price
econom valu therapeut drive share toward low cost servic provid
vs consensusconsensusbarclay research barclay laboratori corp america hldg
uniqu busi offer believ breadth scale capabl labcorp
offer drug develop provid competit advantag versu peer proof point
includ diagnost post revenu growth best sinc drug
diagnost labcorp quest far away low cost
provid test consolid drive growth acceler
see number advantag scale diagnost test labcorp
quest far away low cost provid test scale allow nation
lab leverag autom procur regulatori know-how payor relationship
advanc logist lab hospit peer compet labcorp
deliv laboratori test lower cost smaller less effici competitor
combin compani nation network comprehens test menu
cost advantag allow compani provid signific valu provid payor
patient labcorp attract partner payor look lower cost pursu
in-network strategi someth believ facilit share gain
compani time see figur labcorp quest
size next largest independ laboratori
alway tug war test term site care
independ lab hospit system decad nation lab lose share
hospit peer believ confluenc factor start revers trend
industri format mid nation lab
aggreg scale built nationwid patient servic center access start mid-
hospit system becam aggress consolid physician practic
began insourc test bolster revenu ancillari servic go forward
believ pendulum go swing back direct nation lab
driven ps patient consumer payor strategi price transpar
pama
patient consumer healthcar given rise high-deduct health plan
increas patient cost share employ patient control
seek care past result believ patient consum make
economically-motiv decis relat healthcar servic includ lab
payor strategi payor increasingli focus laboratori spend
believ network strategi favor aggreg share nation lab
clear cost valu proposit drive test volum nation lab
addit labcorp quest roughli patient servic center nationwid
allow consum access test payor also benefit access
comprehens test menu high qualiti standard payor taken number
strategi drive volum toward nation lab includ refer price prior-
author in-network strategi high-deduct health plan laboratori
decis support tool strategi aim shift servic low cost provid
see trend acceler exampl institut new prior-
author polici molecular test novemb labcorp exempt
addit implement labcorp beaconlb support tool
florida aspir expand texa addit state time
price transpar pama believ increas price transpar
acceler trend drive volum toward nation lab notabl
exampl implement protect access medicar act pama
cut medicar reimburs outsiz impact hospit laboratori
highlight rel valu proposit variou test set believ pama
barclay laboratori corp america hldg
continu catalyz period consolid favor nation lab
low cost provid organ consolid could come form greater
outsourc reduct competit addit believ pama continu
catalyst hospit lab sell lead inorgan consolid full
thought pama pleas see page outlook publish januari
outlook stock select critic oper sentiment align
shown figur labcorp reimburs commerci payor well
hospit lab independ laboratori cross
shield bcb north carolina part effort improv price transpar
healthcar servic releas reimburs data differ servic provid level
analyz reimburs routin laboratori test found labcorp
close lowest cost provid servic believ uniqu valu
proposit allow labcorp continu aggreg share time
note bio-refer opko base consensu
cross shield bcb nc rate data
bcb north carolina barclay research
 believ payor contract evolv toward valu away
rate drive share aggreg toward nation lab
see real strateg posit nation lab labcorp quest exclus
contract nation payer aetna respect open in-network
access lab duopoli negoti oligopoli nation lab
histor lost rate discuss given threat move out-of-network
process cede unit price time payor extract valu benefit
lab scale payor open in-network statu lab decis would
indic commerci insur custom employ demand broader
access network labcorp quest jointli provid labcorp quest
regain foot futur negoti discuss larg payor
market like nation exclus contract begin
difficult us see nation lab get penal way back well
look back histor stock perform believ market recognit
decis move sole provid relationship larg payor
favor lab term set balanc power almost billion
market valu destroy upon format labcorp/unitedhealth
despit major contract win labcorp
millionslabshospitalstest medicarelhlowhighlowhighblood test cbc culture/coloni nc rate barclay laboratori corp america hldg
outperform day contract sign
quest in-lin day aetna contract sign given quest
labcorp trade upon respect contact loss clear
market valu destruct independ lab aggreg due move
stock perform around labcorp/unh deal
index
stock perform around quest/aet deal
index
take contract renew labcorp regardless
outcom opportun help balanc risk compani labcorp
unitedhealth sole nation lab provid sinc januari contract extend
end ceo dave king note recent discuss payor
acceler despit januari implement renew import
custom rev risen top recent investor question weve field
thesi key debat whether labcorp remain unitedhealth sole nation lab
provid whether quest re-join network believ like
outcom aetna contract open allow
nation lab access believ lab comment negoti
valu rate goal maintain increas price upon renew support
favor outcom sharehold also believ situat labcorp
complet move network
cadenc announc uncertain believ commerci insur
competit environ make like nation payor adopt
strategi relat lab contract earn labcorp ceo dave king note
acceler recent dialogu reach formal contract believ
part acceler due want certainti laboratori network
negoti commerci contract employ one nation payor open
lab network labcorp quest payor remain nation
exclus one lab would potenti put payor disadvantag
network breadth perspect rel peer note
labcorp quest in-network provid believ unlik one
payor would want stand alon weaker lab network breadth rest
perform lh perform lh flat flat barclay laboratori corp america hldg
labcorp revenu mm total
quest revenu aetna mm total
broadli believ evolv manag care contract practic go
creat ration price environ clinic laboratori industri
histor provid healthcar reimburs util basi fee-for-
servic regardless patient outcom rel countri develop world
led high level healthcar spend weaker perform key health
indic goal value-bas care initi incentiv provid
improv qualiti care simultan lower cost healthcar
system isnt one specif mechan drive chang high-qual
low-cost provid laboratori servic hard imagin scenario labcorp
doesnt win environ lay sever principl mechan value-
base care describ labcorp posit context
improv prevent care treatment chronic diseas take
proactiv approach monitor patient health healthcar system reduc
futur spend medic visit costli emerg treatment chronic
diseas believ util laboratori servic would critic aspect
approach
bundl payment cost share arrang
arrang provid reimburs episod care singular payment
provid meant cover entir cost care often includ follow-up
care need scenario provid incent order necessari
lab test lowest cost provid similar medicar reimburs
dynam inpati laboratori test cost share arrang provid
receiv bonu deliv servic lower cost introduc similar
incent select low cost provid
payment align outcom futur value-bas care mechan could focu
align price healthcar product servic valu provid
patient given recent focu drug price believ would like start
point program natur medic access drug develop
servic covanc equip help biopharma compani demonstr valu
drug addit implement diagnost would equal play
field labcorp given compani hospit competitor receiv premium
reimburs similar servic
 rev total lab aet revsaet total barclay laboratori corp america hldg
continu care use data leverag healthcar technolog ehr
patient treat seamlessli across site care improv effici
healthcar system reduc redund cost expertis nation lab
posit well environ greater focu healthcar data share
addit data increasingli use improv patient manag labcorp
natur partner given wealth diagnost data given compani patient reach
labcorp experi million patient encount annual aggreg
databas billion lab test result
person medicin
learn
differ materi impact efficaci differ treatment
learn patient like benefit given treatment elimin
wast healthcar system improv patient outcom diagnost labcorp
exposur trend genom test portfolio addit
combin compani expertis companion diagnost believ labcorp
well-posit support develop target therapeut
refer price exampl mechan could use payor shift
volum toward low cost provid recent studi dr jami robinson uc
berkeley publish journal american medic associ jama intern
medicin show implement refer price polici laboratori
test result reduct price spend employ employe well
consolid toward nation lab dr jami robinson studi compar laboratori
price select employe larg retail claim data
period time refer price mechan use insur compani
cap amount contribut given diagnost test procedur leav
patient respons remaind cost exampl refer price
vitamin test order avoid cost excess normal out-of-pocket cost
deduct co-pay coinsur patient would need choos provid
offer test less patient get test done insur
would pay patient would respons remain
increas patient cost share lab test price transpar refer
price framework clearli incentiv patient choos lower cost provid
patient avoid fee associ refer price
lower price test reduc patient payment toward deduct third year
follow implement refer price averag price paid per lab test
reduc prior refer price averag price per test
reduc year three program addit total
spend laboratori test declin million three year period out-of-
pocket cost patient reduc million employ spend
reduc million total lab test includ studi repres
total laboratori claim retail test overlap
retail claim use assum similar trend among
remain test studi conclud total estim save million
barclay laboratori corp america hldg
averag price diagnost test follow refer price
journal american medic associ jama barclay research
labcorpceo dave king value-bas care combin world-class diagnost drug develop capabl critic acceler progress precis person healthcar help choos right test right patient right time offer innov molecular genet test deliv next-gener life-sav drug labcorp critic player enabl target tailor high-valu care qualiti scale expertis standard platform payer provid collabor support goal bring differenti valu value-bas care term value-bas care see shift term payer provid think reimburs think context spend drive decis enhanc valu proposit beyond simpli deliveri lab result precis medicin companion diagnost abil deliv right test right patient right time also deliv thing like chronic kidney diseas solut kidney stone recurr solut actual help provid deliv care accord guidelin valu covanc add valu abl bring health system larg physician group opportun particip trial get acut ill patient access cutting-edg medic whole rang capabl around combin enterpris view posit us better anybodi els deliv value-bas care environ questceo steve rusckowski continu wide variat price commerci side nearest competitor lowest price hospit highest price regard consum get smarter variat price health insur compani get smarter well move away fee-for-servic value-bas deliveri system longer volum cost serv valu bring tabl also relat stakehold chang see big chang dialogu healthcar insur compani relat move fee-for-servic valu see consolid hospit marketplac view futur integr deliveri system final see consum becom increasingli bigger import part busi everi day technolog continu underpin busi strong develop compani genom tremend amount inform inform import busi diagnost inform servic import appli data servic popul health also look way bend cost curv barclay laboratori corp america hldg
 drug develop labcorp scale across continuum
unmatch new busi award best breed set
believ breadth scale capabl labcorp offer drug
compani provid earli develop clinic develop central laboratori
servic labcorp opportun leverag multipl touch point client
order cross-sel differ offer compani provid safeti assess
servic molecul studi end progress clinic develop
natur opportun labcorp continu work client molecul
addit believ compani advantag leverag preclin
clinic develop relationship win central laboratori busi manag
clinic trial well associ test allow labcorp bring cohes
approach client
believ three covanc segment necessari scale formid
competitor cro industri term revenu labcorp central laboratori
safeti assess clinic develop
labcorp market-lead central laboratori busi believ
produc number cost advantag relat footprint reduct
laboratori scalabl follow acquisit covanc combin compani
work consolid central laboratori nine five complet
complementari revenu base effort provid meaning cost advantag
better procur elimin duplic overhead improv
effici run laboratori greater scale labcorp finish central
laboratori consolid effort leav five remain laboratori
indianapoli indiana shanghai china geneva switzerland kawago japan
singapor geograph breadth laboratori allow compani meet
barclay laboratori corp america hldg
test need global clinic trial recent acquisit chiltern
believ opportun labcorp gener revenu synergi win
central laboratori busi associ chiltern clinic develop backlog
labcorp player safeti assess servic behind charl river given
high fix cost natur servic scale advantag larger
competitor competitor safeti assess oper larg facil contain
special infrastructur requir in-vivo test result compani
larger facil better equip leverag fix overhead meet increment
demand addit believ compani research model busi nice
compliment safeti assess act trust supplier anim studi
clinic develop labcorp player clinic develop
believ compani necessari capabl compet top-tier cro
global scale compani strengthen capabl recent
acquisit chiltern close septemb believ covanc
therapeut capabl strength oncolog respiratori asia-pacif
presenc employe function servic provid offer posit
segment well cro industri
believ industri lead book-to-bil culmin
competit advantag prime covanc better growth
recent report ttm period labcorp net book-to-bil ratio outpac
peer group post averag book-to-bil admittedli note
labcorp revenu growth modestli slower peer improv
optic ratio said believ benefit partial off-set compani mix
busi drag labcorp book-to-bil rel peer result
central laboratori earli develop busi shorter cycl often
contain lower valu award follow flat organ growth anticip
organ growth
note syneo health medpac result
note lh pro-forma chiltern acquisit
 covanceprahiclriqvsynhmedpacenet million barclay laboratori corp america hldg
note pro-forma mpi research acquisit
better engag patient consumer-friendli way
believ labcorp go demonstr compani invest
technolog tool data patient access allow better engag patient
consumer-friendli way advantag across diagnost drug develop
chang healthcar landscap consum healthcar control
healthcar decis believ favor conveni consumer-
friendli provid servic patient engag also critic clinic trial
adher high qualiti data improv valu proposit biopharma sponsor
labcorp retail strategi newli launch technolog platform believ
compani well-posit benefit dynam labcorp invest
tool technolog design improv patient experi
believ prompt effici synergi within organ proof point
see includ statist patient opted-in clinic trial enrol
patient seen labcorp walgreen either new labcorp
seen last year compani execut million covanc
cost synergi
labcorp made major invest tool technolog foster
better patient engag valuabl diagnost drug
labcorp make major invest tool technolog goal
optim valu
patient/investig data streamlin oper
process improv patient engag overal enhanc custom
experi importantli sever tool use across lab cro
segment improv valu proposit combin compani expect labcorp
new technolog invest full display analyst day believ one
way compani convinc investor lab cro better togeth
sever tool detail
diagnost data patient recruit tool deliv lab result
million patient per year labcorp aggreg databas billion
 solut iqv/dgx ppdicon river/ mpi researchlabcorp/covanceenvigo million barclay laboratori corp america hldg
lab test result databas identifi patient level avail
real-tim compani leverag laboratori data covanc busi
identifi patient specif condit locat help speed
labcorp/cov relationship investig compani work
investig site global inform use determin
site like product match high efficaci site
laboratori data covanc speed studi recruit trial start-up
timelin labcorp patient consent databas differenti capabl
cro industri allow compani contact patient directli clinic
research opportun variou cro abil creat heat map
patient provid insight site like recruit well base
patient region labcorp patient consent
contact compani work number initi discuss
 autom check-in tool labcorp new precheck patient come
platform improv conveni patient optim effici employe
allow compani get closer custom labcorp express patient
easili scan driver licens insur card kiosk upon enter
psc labcorp precheck allow patient provid necessari person
insur inform on-line prior arriv psc lastli labcorp patient
platform allow individu make appoint check-in view test result
comput tablet mobil devic leverag electron technolog
interact patient platform prompt opt-in contact
clinic research opportun capabl didnt exist patient use
check paper form labcorp believ use platform go
acceler pace sign-up consent patient databas
 laboratori decis support tool labcorp initi laboratori test order
support program goal help physician order appropri test
patient base guidelin industri best practic compani launch
beaconlb program unitedhealthcar earli result shown physician
adher guidelin improv addit patient care benefit physician
commonli chose in-network lab reduc out-of-pocket cost
patient also increas likelihood labcorp receiv order labcorp
initi launch beaconlb program unitedhealthcar florida
sinc expand texa detail beaconlb pleas see report
octob lh beaconlb pilot w/ expand texa
barclay laboratori corp america hldg
use technolog quot
 labcorp consum strategi believ compani
opportun get closer patient think drive volum
better patient engag new patient access
believ labcorp strategi bring laboratori servic closer patient well-
align today healthcar environ consum increasingli look
conveni compani explor number initi design
increas exposur new exist patient highest profil retail
partnership walgreen remind june labcorp sign agreement
walgreen open psc seven store end addit retail
agreement labcorp hint next step would move in-hom test
repres improv patient conveni someth believ
could actual repres cost save opportun time lastli believ patient-
direct test could becom signific opportun time detail
labcorp walgreen partnership pleas see report thought
labcorp retail pilot walgreen
earningsceo dave kingcov continu invest tool technolog capit competit advantag confer comprehens patient data extens site investig perform data industri leadership concurr develop therapeut companion diagnost diagnost third strateg initi develop broader platform deepen consum relationship made strong progress improv user experi servic continu roll new tool technolog includ labcorp express labcorp precheck labcorp patient releas mobil app version labcorp patient later quarter ad consum conveni addit option current avail patient portal barclay laboratori corp america hldg
largest retail pharmaci unit state
diagnost test offer access point retail offer healthcar servic
site labcorp patient servic center across signific portion
medic build strip mall move retail locat
exist patient provid better access labcorp also increas exposur
potenti new patient retail bring psc locat great way
improv foot traffic labcorp retail agreement walgreen shown earli
promis improv convict compani abil drive volum
consum strategi confer januari labcorp highlight
patient site move walgreen either new labcorp
seen prior month
 leverag phlebotomist revenu gener basic healthcar servic
addit blood draw believ labcorp could leverag phlebotomist provid
healthcar servic retail locat exampl retail site could leverag
phlebotomist perform basic health servic run clia-waiv respiratori test
flu season estim around half labcorp lab employe base
 in-hom collect devic increas patient conveni labcorp hint
opportun around in-hom self-collect sampl would allow
compani get even closer patient experi would similar
compani experi dri blood spot test would clearli
repres anoth step patient conveni believ would also
signific cost save opportun associ initi previous
mention believ labcorp roughli phlebotomist repres half
compani lab employe base result larg workforc roughli half
compani cost structur compris labor self-collect devic becam
rankpharmacycitystatepharmacistsstoreslab aid corporationcamp hold companyhoffman capit managementnew shopp internationalsaint storesgreen de drug storessan eagl pharmaci brother barclay laboratori corp america hldg
wide adopt compani would abl ration phlebotomist
consum test opportun patient becom inform
healthcar option increasingli proactiv health believ patient-
direct test becom signific opportun nation lab
background type test order discret patient without
requisit physician current allow roughli half state
 sever state look approv view retail locat
natur avenu offer patient-direct test nation lab leverag
foot traffic store drive volum compar patient servic center psc
tuck medic offic strip mall believ patient shop walgreen
much like stop order lab test
addit patient-direct routin test labcorp success area
consum genom labcorp abl leverag long-standing relationship
benefit compani recent success consum test
market driven theme consumer individu desir learn
genet make-up result signific growth throughout
confer earli januari compani actual said partnership
capabl drive growth top line addit given consum
test cash pay growth subject payor contract chang
opportun person visit labcorp new patient servic center
experi thornton co came away impress compani progress
cohes experi walgreen brand partnership
everywher throughout store labcorp walgreen brand outsid behind
check-out counter along wall pharmaci counter obvious
labcorp set patient servic center locat back store next
pharmaci check-in take place pharmaci counter patient sign
driver licens scanner labcorp locat take much floor
space patient room corner facil
 believ tool technolog support sustain margin
expans labcorp
see opportun labcorp drive effici improv margin
compani busi segment offset margin headwind pama notabl
labcorp outlin million increment launchpad save covanc
next year repres around tailwind overal ebitda growth per year
diagnost believ labcorp abl drive on-going margin
improv primarili
technolog
launchpad within compani diagnost segment formal end
compani achiev million net save believ compani still room
improv effici time insid laboratori believ labcorp
opportun leverag autom advanc diagnost technolog
drive effici volum grow outsid laboratori believ labcorp
long-term opportun drive product patient servic footprint
logistics/couri network lastli innov bill practic
compani like improv bad debt time labcorp support effici
cost structur simpli switch electron handl patient inform
addit initi like auto-adjud allow labcorp verifi patient
barclay laboratori corp america hldg
reimburs coverag real-tim perform lab test import
note improv like off-set headwind pama
believ covanc opportun close margin gap peer given
major cost structur labor larg view variabl
cost margin improv natur come top line growth better leverag
sg line addit top line leverag labcorp identifi area potenti
oper improv earn labcorp provid detail
second phase compani covanc launchpad initi follow million
cost save achiev labcorp aim gener addit
million save end goal improv process
system result enhanc qualiti reduct segment cost basi
first phase covanc launchpad aim reduc headcount facil footprint
second phase expect focu deliv low cost approach
servic code lousi servic manag believ number
way leverag low-cost site technolog deliv flexibl effici
cost-structur part analysi includ deep review covanc
busi decid whether way improv perform long-rang
plan compani believ result review yield meaning well-
plan save three-year period look peer group cash ebitda margin
labcorp well group averag
note medpac base consensu syneo health base estim
revenu reflect account standard prior
conclus labcorp beneficiari
believ labcorp beneficiari two trend compani
valu proposit creat compel valuat case stock mid-
singl digit organ revenu growth substanti free cash flow gener capit
deploy model ep growth around beyond believ labcorp
strategi applic broader rang life scienc market time provid long
runway futur growth final labcorp manag team steadi track record
execut improv confid strategi
river dsa medpac iqviaiconsyneo clinic covanc lh health ebitda ebitda marginsaverag barclay laboratori corp america hldg
believ combin factor drive double-digit long-
term ep growth compani
histor ep y/i growth
histor free y/i growth
ultim believ combin top-lin growth margin expans capit
deploy result high-singl low-doubl digit earn growth
dont anticip labcorp give specif revenu ep guidanc believ compani
lay framework long-term growth fundament busi
believ combin low- mid-singl digit organ growth
diagnost segment combin mid- high-singl digit growth covanc
result mid-singl digit organ growth profil compani
diagnost low-singl digit growth diagnost would repres base case
scenario emb headwind pama next three year
upsid target would come organ industri consolid result
increas outsourc hospit laboratori drug develop model
organ growth support strength recent net book
beyond continu strength busi win would push revenu growth
estim high-singl digit
despit headwind pama expect labcorp show steadi margin
improv time diagnost segment margin expans expect
limit reimburs headwind pama expect
headwind adjust ebitda growth headwind
forecast labcorp diagnost segment ebitda margin
roughli flat view major margin improv go
come covanc side busi model adjust ebitda
margin improv annual margin well peer upsid
target would driven strong top line growth execut chiltern synergi
covanc launchpad save result quicker progress toward group
labcorp exit net debt-to-ttm ebitda ratio leav
compani flexibl pursu share repurchas compani
emphas commit integr mt sinai paml chiltern
acquisit would surpris compani activ tuck-in
throughout absent would expect labcorp prioriti debt
growth y/i epsep growth growth y/i millionsfre growth y/i barclay laboratori corp america hldg
repay share repurchas compani success
deploy roughli billion go expect contribut
top-lin growth
 believ labcorp strategi applic broader rang life
scienc market time provid long runway futur growth
see signific address market life scienc labcorp consolid
time view acquisit covanc first step labcorp transit
becom global life scienc oper addit geograph expans clinic
laboratori servic believ test area would repres natur
parallel labcorp expand time note sever categori
higher growth area less exposur reimburs
lab consum testing/clin trial exposur view consum
test market attract natur extens labcorp capabl
clinic laboratori consum compani ancestri dna
deliv test result answer differ question laboratori process gener
result similar advanc test clinic set result
surpris nation lab partner sever consum test
compani combin labcorp covanc creat leader
develop commerci companion diagnost said
develop side believ room compani add enhanc
capabl foundat medicin compani could leverag clinic
develop relationship expand cdx partnership
 clinic trial logist believ combin labcorp expertis
logist covanc clinic develop experi make compani natur
oper clinic trial logist busi busi provid outsourc
suppli chain plan manag biopharma compani run
clinic trial believ labcorp could leverag logist expertis clinic
laboratori footprint world-wide central laboratori footprint effici
provid servic believ would compel cross-sel
opportun covanc clinic develop busi central laboratori
network could act facilit logist
busi would way labcorp bridg oper expertis
diagnost side covanc biopharma relationship number
similar run diagnost laboratori contract drug manufactur
oper scale procur regulatori know-how oper excel
core tenet busi model addit labcorp deep biopharma
custom relationship covanc move space would creat
synergi custom perspect final own clinic trial
logist busi would allow covanc manag entir clinic trial process
core cro capabl manufactur drug trial pack
ship drug investig site similar cro industri
believ industri benefit posit structur tailwind
appli test food environment forens biopharma appli
test categori offer exposur favor structur growth trend life scienc
custom less reimburs price sensit tend focus
regul qualiti environment food pharmaceut test area
primari focu qualiti meet regulatori requir consum becom
conscious around safeti qualiti compani increas pressur
barclay laboratori corp america hldg
maintain control qualiti assur order protect brand remind
labcorp alreadi exposur trend compani food
 labcorp deep manag bench give us confid
overal rank labcorp manag team top-tier life scienc tool
diagnost coverag compani consist execut compani
diagnost segment impress beyond ceo dave king cfo glenn eisenberg
manag team strong cro industri veteran john ratliff ceo covanc
diagnost veteran gari huff run labcorp diagnost extens experi
health system across countri
namepositiontenur lhbackgrounddav kingchairman yearsceo sinc previous compani gener counsel/chief complianc offic eisenbergchief yearsjoin labcorp cfo march previous serv cfo timkin companyjohn ratliffchief execut offic yearsjoin labcorp octob spent year quintil iqvia role cfo recent ceo huya biosciencegari huffchief execut offic yearsbeen lead lcd sinc march rejoin labcorp svp labcorp diagnost hospit health system grouplanc berberianchief inform yearsjoin labcorp februari previous dodsonchief account yearsjoin labcorp corpor control come chief account offic june barclay laboratori corp america hldg
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
